Validation of a New Device to Measure Neuromuscular Disease Progression (ATLIS)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00606918 |
Recruitment Status :
Completed
First Posted : February 5, 2008
Last Update Posted : May 12, 2011
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Amyotrophic Lateral Sclerosis & Other Neuromuscular Disorders |
Study Type : | Observational |
Estimated Enrollment : | 120 participants |
Observational Model: | Case-Control |
Time Perspective: | Cross-Sectional |
Official Title: | Validation of a New Device to Measure Neuromuscular Disease Progression |
Study Start Date : | January 2008 |
Actual Primary Completion Date : | September 2010 |
Actual Study Completion Date : | September 2010 |

Group/Cohort |
---|
1
Individuals with ALS
|
2
Healthy Adults
|
- isometric strength measures [ Time Frame: cross sectional ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- All subjects must be at least 18 years old and able to provide informed consent
- All subjects have no health conditions that limit their ability to safely exert maximal force using the muscles in their arms and legs.
- Subjects with a diagnosis of laboratory supported probable, probable or definite ALS according to the World Federation of Neurology El Escorial, as determined by their referring neurologist at MGH.
- All subjects must be able to speak and understand English.
Exclusion Criteria:
- Presence of significant arthritis, orthopedic conditions, or cardio-pulmonary conditions or other medical conditions that may limit the ability to maximally exert force safely.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00606918
United States, Massachusetts | |
Massachusetts General Hospital - East | |
Charlestown, Massachusetts, United States, 02129 |
Principal Investigator: | Patricia L. Andres, MS, DPT | Mass. General Hospital |
Responsible Party: | Patricia L. Andres, Massachusetts General Hospital |
ClinicalTrials.gov Identifier: | NCT00606918 |
Other Study ID Numbers: |
MDA-4343 |
First Posted: | February 5, 2008 Key Record Dates |
Last Update Posted: | May 12, 2011 |
Last Verified: | May 2011 |
Strength testing Disease progression ALS Healthy Adults |
Motor Neuron Disease Amyotrophic Lateral Sclerosis Neuromuscular Diseases Disease Progression Pathologic Processes Disease Attributes Neurodegenerative Diseases |
Nervous System Diseases Spinal Cord Diseases Central Nervous System Diseases TDP-43 Proteinopathies Proteostasis Deficiencies Metabolic Diseases |